148674-39-9

Basic information

• Product Name: SB 206328
• Synonyms: (Z)-Eprosartan;(Z)-α-[[2-Butyl-1-[(4-carboxyphenyl)Methyl]-1H-iMidazol-5-yl]Methylene]-2-thiophenepropanoic Acid;(αZ)-α-[[2-Butyl-1-[(4-carboxyphenyl)Methyl]-1H-iMidazol-5-yl]Methylene]-2-thiophenepropanoic Acid;SB 206328;Eprosartan USP RC F;Eprosartan related coMpound F;Eprosartan Related Compound F: Eprosartan Cis-Isomer
• CAS NO: 148674-39-9
• Molecular Formula: C23H24N2O4S
• Molecular Weight: 424.51266
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 148674-39-9.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 660.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: 3.10±0.37(Predicted)
• CAS DataBase Reference: SB 206328(CAS DataBase Reference)
• NIST Chemistry Reference: SB 206328(148674-39-9)
• EPA Substance Registry System: SB 206328(148674-39-9)

Safety Data

• Hazardous Substances Data: 148674-39-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 148674-39-9 differently. You can refer to the following data:
1. (Z)-Eprosartan is the Z-isomer of Eprosartan (E590100), as an impurity in tablets.
2. (Z)-Eprosartan (Eprosartan USP Related Compound F) is the Z-isomer of Eprosartan (E590100), as an impurity in tablets.

Upstream product

• 133040-01-4 eprosartan 
• 133040-05-8 4-[5-(1-Acetoxy-2-methoxycarbonyl-3-thiophen-2-yl-propyl)-2-butyl-imidazol-1-ylmethyl]-benzoic acid methyl ester 
• 133040-06-9 methyl (E)-3-<2-butyl-1-<(4-carbomethoxyphenyl)methyl>imidazol-5-yl>-2-(2-thienylmethyl)-2-propenoate 
• 68282-49-5 2-n-butyl-1H-imidazole-4-carbaldehyde 
• 148674-60-6 2-(thienylmethyl)cyanoacetic acid 
• 133040-04-7 2-butyl-1-(4-carbomethoxybenzyl)-5-<2-carbomethoxy-1-hydroxy-3-(2-thienyl)propyl>imidazole 
• 133040-02-5 2-butyl-4-chloro-1-<(4-carbomethoxyphenyl)methyl>-1H-imidazole-5-carboxaldehyde 
• 133040-03-6 2-n-butyl-1-[(4-carbomethoxyphenyl)methyl]-1H-imidazol-5-carboxaldehyde 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 16862-05-8 methyl 3-(2-thienyl)propanoate 
• 143468-96-6 3-ethoxy-3-oxo-2-(thien-3-ylmethyl)propanoic acid 
• 133486-13-2 ethyl (αE)-α-[[2-n-butyl-1-[[4-(methoxycarbonyl)phenyl]methyl]-1H-imidazol-5-yl]methylene-2-thiophene]propionate 

Relevant articles and documents

Multicomponent Pharmaceutical Adducts of α-Eprosartan: Physicochemical Properties and Pharmacokinetic Study

Pharmaceutical adducts of α-eprosartan (EPR) with nicotinamide (NIC) and p-hydroxy benzoic acid (PHB) were prepared by a liquid assisted grinding technique. Prior to conducting this study, the single crystal structure of EPR was determined. This study was designed to improve the pH-dependent solubility and dissolution rate of EPR and hence its oral absorption across the gastrointestinal tract. Initially, differential scanning calorimetry and powder X-ray diffractometry were used as a screening tool for rapid cocrystal or eutectic mixture screening. The eutectic mixture of EPR with PHB in a 1:3 stoichiometry ratio shows a better solubility and dissolution rate in all aqueous buffers as compared to EPR/NIC cocrystals and pure EPR. The EPR/NIC cocrystal in a 1:1 stoichiometry ratio shows a better dissolution rate initially as compared to pure EPR but does revert back to EPR within the first 30 min in pH 1.2 and 6.8. Absorption and desorption profile of EPR adducts are reversible, suggesting no solid state transformation under experimental conditions. A significant increase in oral bioavailability in overnight fasted Sprague-Dawley rats is achieved with the EPR/NIC cocrystal (2.4-fold) and EPR/PHB eutectics (6.1-fold), even when the cocrystal transformation is suspected based on in vitro studies.

PROCESS FOR THE PREPARATION OF EPROSARTAN

Disclosed herein is an improved novel synthetic process for the preparation of Eprosartan, which comprises treating 2-n-butyl-4-formylimidazole of formula (II) with N-protecting group selected from the group consisting of C1-C4 alkyl ester derivative of m

PROCESS FOR EPROSARTAN INTERMEDIATE

The present invention provides an improved process for preparation of (E)-α-[[2-butyl-1-[[4-(methoxycarbonyl)phenyl]methyl]-1H-imidazole-5-yl]methylene]-2-thiophene propanoic acid ethyl ester in high purity and in high yield. Thus, for example, 4-[[2-buty